Chemiluminescence kit for the detection of SS-A/Ro52 antibodies in human serum or plasma.

Coming soon
Catalog Number: CL-Ro5250
Size: 50 tests
Regulatory status: CE IVD
Clinical topic: Immunology & Autoimmune Diseases
  • Detection of anti-SS-A/Ro52 antibodies, IgG class
  • Evaluating patients with signs and symptoms of a connective tissue disease and positive test for antinuclear antibodies
  • A positive result for SS-A/Ro52 antibodies indicates connective tissue disease, including systemic scleroderma and myositis
  • In a woman with SLE prior to delivery, a positive result for SS-A/Ro52 antibodies indicates the risk of congenital atrioventricular block (CAVB) development
  • Intended for human serum and plasma
  • Recombinant antigen SS-A/Ro52 (52 kDa) antigen is used

SS-A/Ro antigen is a ribonucleoprotein (RNP) complex localized in nucleus and cytoplasm. It consists of hYRNA (small cytoplasmic RNA) and two protein antigens of 52 kDa and 60 kDa (Ro52 and Ro60).

Autoantibodies against Ro60 a Ro52 are often found together; anti-SS-B/La antibodies may also occure. Presence of the SS-A/Ro autoantibodies is typical for Sjögren’s syndrome (50 – 70%) and systemic lupus erythematodes (40 – 50%), especially for certain clinical subunits (subacute cutaneous lupus, neonatal lupus), and rheumatoid arthritis. Anti-SS-A/Ro antibodies can be detected approximately 3 years before the SLE diagnosis is reached. SS-A/Ro antibodies are also associated with features of extraglandular inflammation in SLE patients including vasculitis, purpura, cytopenias, and adenopathy.

While anti-Ro60 antibodies are primarily specific for systemic lupus erythematodes and Sjögren’s syndrome, anti-Ro52 antibodies was proved to be individually present (without anti-Ro60) in systemic scleroderma (20%) and myositis (35%), especially in anti-Jo-1 positive patients. Anti-Ro52 as well as anti-SS-B/La antibodies significantly raise the risk of congenital atrioventricular block (CAVB) development. They may be also present in autoimmune liver disease.

Antigen Used: Highly purified native antigen SS-A/Ro60 (60 kDa) and recombinant antigen SS-A/Ro52 (52 kDa).

Technical specifications

Technical data
Related Products

Technical data

Assay stability (on board)30 days
Sample matrix Serum, Plasma
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions


References to CLIA SS-A/Ro52

  • Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev. 2009 Jun;8(7):632-7. doi: 10.1016/j.autrev.2009.02.010. Epub 2009 Feb 12. PMID: 19393201.
    See more on PubMed
  • Zampeli E, Mavrommati M, Moutsopoulos HM, Skopouli FN. Anti-Ro52 and/or anti- Ro60 immune reactivity: autoantibody and disease associations. Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):134-141. Epub 2020 Feb 18. PMID: 32083547.
    See more on PubMed
  • Menéndez A, Gómez J, Escanlar E, Caminal-Montero L, Mozo L. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection. Autoimmunity. 2013 Feb;46(1):32-9. doi: 10.3109/08916934.2012.732131. Epub 2012 Nov 12. PMID: 23039326.
    See more on PubMed
  • Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham BN, Giusti D. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases. Front Immunol. 2019 Mar 12;10:444. doi: 10.3389/fimmu.2019.00444. PMID: 30915082; PMCID: PMC6423153.
    See more on PubMed
  • Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011 Jul;10(9):509-13. doi: 10.1016/j.autrev.2011.03.004. Epub 2011 Apr 5. PMID: 21447407.
    See more on PubMed
  • Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int. 2017 Aug;37(8):1323-1333. doi: 10.1007/s00296-017-3718-1. Epub 2017 Apr 17. PMID: 28417151.
    See more on PubMed


Find documents for the batch

Do you want to learn more?
We're here for you

Please fill in
all fields
marked *
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.